Teriflunomide Mylan Uni Eropa - Italia - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomide - sclerosi multipla recidivante-remittente - immunosoppressori - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Teriflunomide Accord Uni Eropa - Italia - EMA (European Medicines Agency)

teriflunomide accord

accord healthcare s.l.u. - teriflunomide - sclerosi multipla recidivante-remittente - immunosoppressori selettivi immunosoppressori - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Sitagliptin / Metformin hydrochloride Sun Uni Eropa - Italia - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Jaypirca Uni Eropa - Italia - EMA (European Medicines Agency)

jaypirca

eli lilly nederland b.v. - pirtobrutinib - linfoma, cellule del mantello - inibitori della proteina chinasi - treatment of mantle cell lymphoma (mcl).

CLEFIREM Italia - Italia - AIFA (Agenzia Italiana del Farmaco)

clefirem

bausch health ireland limited - teriflunomide - teriflunomide

ELSTABYA Italia - Italia - AIFA (Agenzia Italiana del Farmaco)

elstabya

pharmathen s.a. - preparati inibenti la produzione di acido urico - preparati inibenti la produzione di acido urico

FEBUXOSTAT TEVA Italia - Italia - AIFA (Agenzia Italiana del Farmaco)

febuxostat teva

teva b.v. - preparati inibenti la produzione di acido urico - preparati inibenti la produzione di acido urico

FEBUXEN Italia - Italia - AIFA (Agenzia Italiana del Farmaco)

febuxen

s.f. group s.r.l. - preparati inibenti la produzione di acido urico - preparati inibenti la produzione di acido urico